Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn’s disease
Open Access
- 30 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-14
Abstract
Background: Dysbiosis of the gut microbiota is pivotal in Crohn’s disease (CD) and modulated by host physiological conditions. Hyperbaric oxygen therapy (HBOT) is a promising treatment for CD that can regulate gut microbiota. The relationship between HBOT and the gut microbiota in CD remains unknown. Methods: CD patients were divided into an HBOT group (n = 10) and a control group (n = 10) in this open-label prospective interventional study. The fecal samples before and after HBOT were used for 16 S rRNA gene sequencing and fecal microbiota transplantation (FMT). A colitis mouse model was constructed using dextran sulfate sodium, and intestinal and systematic inflammation was evaluated. The safety and long-term effect of HBOT were observed. Results: HBOT significantly reduced the level of C-reactive protein (CRP) (80.79 ± 42.05 mg/L vs. 33.32 ± 18.31 mg/L, P = 0.004) and the Crohn’s Disease Activity Index (CDAI) (274.87 ± 65.54 vs. 221.54 ± 41.89, P = 0.044). HBOT elevated the declined microbial diversity and ameliorated the altered composition of gut microbiota in patients with CD. The relative abundance of Escherichia decreased, and that of Bifidobacterium and Clostridium XIVa increased after HBOT. Mice receiving FMT from donors after HBOT had significantly less intestinal inflammation and serum CRP than the group before HBOT. HBOT was safe and well-tolerated by patients with CD. Combined with ustekinumab, more patients treated with HBOT achieved clinical response (30%vs.70%, P = 0.089) and remission (20%vs.50%, P = 0.160) at week 4. Conclusions: HBOT modulates the dysbiosis of gut microbiota in CD and ameliorates intestinal and systematic inflammation. HBOT is a safe option for CD and exhibits a promising auxiliary effect to ustekinumab. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200061193. Registered 15 June 2022, https://www.chictr.org.cn/showproj.html?proj=171605.Keywords
Funding Information
- National Natural Science Foundation of China (82230019, 82170599, 82070651)
This publication has 55 references indexed in Scilit:
- Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn’s DiseaseCell Host & Microbe, 2015
- Correlation Between Intraluminal Oxygen Gradient and Radial Partitioning of Intestinal MicrobiotaGastroenterology, 2014
- Mechanisms of action of hyperbaric oxygen therapy.2014
- Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomesNature Biotechnology, 2014
- Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2014
- Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based StudiesGastroenterology, 2013
- Oxybiotest project: microorganisms under pressure. Hyperbaric oxygen (HBO) and simple pressure interaction on selected bacteriaMedical Gas Research, 2012
- Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's diseaseGut, 2011
- Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relativesGut, 2011
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997